DERIVATIVES OF BENZO-1,2-THIAZINE-1,1-DIOXIDE, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Abstract: Esters of 4-hydroxy-2-alkyl-3-aminocarboyl-2H-1,2-­ thiazine-1,1-dioxide having formula (I) where R stands for lower alkyl C₁-C₄; R₁ stands for a linear or a branched alkyl bearing from 1 to 5 atoms of carbon and preferably ter-butyl; Ar stands for an aromatic or heteroaromatic residue bearing from 1 to 3 etheroatoms such as O, S, N, and preferably the residues 2-pyridyl, 2-thiazolyl; and their addition salts with pharmaceutically acceptable acids are endowed with a therapeutic index higher the one of the parent, not esterified compounds.

Description: Derivatives of benso-1,2-thiazine-1,1-dioxide, a process for their preparation and pharmaceutical compositions containing the same The present invention refers to new derivatives of benzo-1,2-thiaxine-l,l-dioxide of gene ral formula: EMI1.1 where R stands for lower alkyl C1-C4; R1 stands for a linear or a branched alkyl bearing from 1 to 5 atoms of carbon and preferably ter-butyl; Ar stands for an aromatic or heteroaromatic residue bearing from 1 to 3 etheroatoms such as C, S, N, and preferably the resi dues 2-pyridyl, 2-thiazolyl; and their addition salts with pharmaceutically accepta ble acids. Specific compounds included in the formula (T) are: 4-pivaloyloxy-2-methyl-2H-1,2-benzothiazine-3 [N-(2-pyridyl)-carboxamide]-1,1-dioxide; 4-py valoiloxy-2-methyl-2H-1,2-benzothiazine-3-[N (2-thiazolyl)-carboxamide]-1,1-dioxide. In the U.S. Patent n. 3,591,584 a new class of compounds of the series of the 3-aminocarbo nyl-1 ,2-benzothiazine-1 , 1-dioxide bearing hete rocyclic residues at the amino-nitrogen has been reported for the first time. Compounds of this kind are endowed with an anal gesic and antiinflammatory activity, and some of them have been used in the therapy of arthrorheumatic affections, in spite of presenting draw backs especially due to the appearance of gastro enteric disorders in the treated patients; disorders, however, very common in other non-steroidic antiinflammatory compounds. After our priority-filing of the present patent application (Italian Application n. 19486 A/82 of February 5, 1982) we have learned from the pu blication of the European Application n. 57059, filed on January 11, 1982, that also some esters of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-[N (2-pyridyl)-carboxamidS -1,1-dioxide have been prepared and pharmacologically tested. These new derivatives, nevertheless, do not pre sent any real therapeutical advantage, since they possess, to a lower or a higher extent, the same characteristics as the startin,r compound; they simply turn out to be more suitable to the topic administration route. It has instead been found, and it is the ob;ject of the present invention, that the esterifica tion of the hydroxyl in position 4 in the struc ture in question with a particular kind of such stituent allows to obtain a new compound with antiinflammatory activity that presents unforeseeable surprising advantages at therapeutic le vel. It has in fact been established that only this particular new derivative corresponding to the formula (I), precisely obtained by means of este rification of the hydroxyl in 4-position with a ter-butyl radical, while it keeps substantially unaltered the anti inflammatory activity, it has a drastically reduced ulcerogenic activity, thus showing a therapeutic index 10.25 times higher than the one of the starting compound. Various ways of synthesis followed to obtain the compounds described in the above-mentioned patents and other similar compounds are known from the prior art. One of these ways can be schematized as follows: EMI3.1 (where R and R' represent for example CH3, whereas R" represents for example H, alkyl, hetero aromatic residue); see U.S. pat. n. 3,591,584, 1971; Lombardino J.G. et al., J. Med. Chem. 14 (12), 1171, 1971. Other alternative ways of synthesis described in patents and in the literature have not offered up to now particular advantages as compared to one indicated above. It has now been found, and it is the object of the present invention, a new method to prepare the compounds of formula (I), which presents so me interesting advantages. According to the invention, the compounds (I) are obtained in conformity to the following reac tion scheme, where R, R1 and Ar have the meaning above specified for the formula (I), whereas X and X1 are halogens, for example Cl or Br. EMI5.1 As it is evident, the main characteristic of the new process of synthesis of the invention is the fact of obtaining, from a pentaatomic derivative, an esaatomic ring already substituted in 3-position with the N-eterocyclic carboxamidic group. This involves a remarkable increase of the yields. The general synthesis scheme is afterwards explai ned in a more detailed way. The starting products (VI) and (VII) are commercially available or they can be prepared according to well-known methods. As a matter of fact the compound (VII) can be ob tained by neutralizing exactly with mineral acids the sodium salt (VI) dissolved in water, filtering, if necessary,the unreacted product, acidifying at pH 1-0 and filtering VII. The intermediate VII is subsequently reacted with the compound X-CH2CONMAr (VIII). This reagent is often commercially available, or its synthesis is well-hlorm or it is easily obtainable according to well-known methods. The reaction between the intermediate (VII) and the product (VIII) is carried out at temperatures ranging from 0 and 80oC, preferably from room tem perature to the boiling temperature ci the sol vent that is used, and, if necessary, in the presence of a stoichiometric or catalytic quantity of a base and/or of an acidity acceptor (B), such as aliphatic, aromatic or heterocyclic tertiary amines, hydroxydes or carbonates of alkali or earth-alkali metals, bicarbonate, acetates, hydrides, amides or alcoxides of alkali metals. As solvents (S) all the ones that are commonly used, such as benzene, toluene, acetone, chloro form, 1 , 2-dichloro-ethane, dimethylformamide, wa ter, methylene chloride, etc. can be used, It is also possible to carry out the reaction in double phase using water and one of the abovementioned solvents. In some cases the solvent can be represented by the reagent itself used in excess. The reaction may be carried out in presence of a catalyst (C), such as, for instance, a base like the ones described under "B", quaternary ammonium or phosphonium salts (especially in the double phase reactions), alkali iodides, or cuprous iodide, etc, The expansion reaction of the thiazolic ring ta kes place by means of treatment of the interme diate (IX) with sodium methoxide in dimethylsulfoxide and by checking the exothermia of the reaction so that the temperature is not higher than 30-350C, The intermediate (X) thus obtained is transfor med at a temperature that is lower than 50C in one of its addition salts with mineral acids (HX1) (preferably HCl), by addition of the acid (or of one of its solutions in solvent) to a so lution of the intermediate (X) in a solvent that allows the precipitation of the previously formed salt. The intermediate (XI) is reacted with an acyl halide (R1COX) or with the anhydride of a caboxylic acid[(R1CO)2O] in a solvent that can be chosen among the ones described before (S) (with the exception of water) and at temperatures ranging from 0 to 700C. Also a catalyst (C) can be used, but more often this is superfluous, When the reaction is over the intermediate (XII) is isolated, and it is immediately transformed in the compound (XIII) by means of treatment with a stoichiometric quantity of a base (B) and/or in the presence of a solvent (S). The intermediate (XIII) is finally reacted with the reagent RX in the presence of bases "B" in the absence or in the presence of solvents "S" and of catalysts "C", at temperatures ranging from 0 to 1OCOC, preferably at room temperature. For this reaction it is possible to use, as solvents, lower alcohols, from which it is possible to crystallize the final product (I). The product of the general formula (I) can be prepared alternatively starting from the intermediate (X), by means of the following reactions: EMI9.1 where R, R1 and Ar have the meanings that have been previously defined for the general formula (I); R2 stands for a lower alkyl; X stands for an halogen such as Cl, Br; B, S, C have the meanings indicate above. The intermediate (X) is reacted with RX in the presence of a base 3, in the absence or in the presence of the solvent S and of the catalyst C, at tempe ratures ranging from 0 to 100oC, preferably at room temperature. The intermediate (XIV) that has been thus obtained is reacted with reagents such as EMI9.2 (acyl halides) or EMI9.3 (carboxylic acids anhydrides) or R1-COOH (carboxylic acids) or R1COOR2 (esters of carboxylic acids), where R2, R1 and X have the same meanings they had before. The base B, the solvent S and the catalyst C are of the above-mentioned kind. Also acid catalysts are suitable (for example mineral acids such as sulphuric, phosphoric and hydroch loric acid). The reaction is carried out between 0-1000C, more often between room temperature and 600C or at the boiling temperature of the sol vent. The final product of the general formula (I) is crystallized from solvents such as alcohols, ethers, methylene chloride, acetone etc., or from their mixtures. The compounds of formula (I) thus obtained can moreover form addition salts with various pharma ceutically acceptable acids such as inorganic acids like hydrochloric acid, sulphuric acid, pho sphoric acid, nitric acid, hydrobromic acid, or organic acids such as oxalic acid, maleic acid, fu maric acid, malic acid, tartaric acid, citric acid, ascorbic acid. These salts can be easily prepared in a wellknown way, for example by adding an aequimolecular quantity or an excess of the acid to a so lution of the compound of formula (I) in an or ganic solvent, such as methanol, ethanol, isopro panol, acetone and similar. The invention is ex plained in a more detailed way by the following examples, which, on the other hand, do not limi tate it. EXAMPLE 1 a) Preparation of intermediate (VII) In a 500 ml beaker provided with magnetic stirrer 0.06 moles of intermediate VI, which are dissolved in about 200 ml of H20, are charged. When the dissolution is complete, 1 N hydrochlo ric acid is slowly added to exact neutrality (checking by means of indicator or pH-meter). The reaction mixture is now left under stirring for about 30' and the solid formed, if any, is filtered off. The filtrate is acidified to pH 1-0. The precipitated VII is filtered, washed with H2 0 and dried in oven under vacuum. Yields vary from 65 to 90%. The product obtained is characterized by means of N.M.R., IR, U.V. spec tra and of elementary analysis. b) Preparation of the intermediate IX In a 1-liter flash with stirrer, thermometer, re flux condenser, dropping funnel, external thermo sthatic bath, 0.25 moles of intermediate (VII), 23 g of potassium carbonate, 200 ml of H2 0 are charged. The reaction mixture is heated to 5000 for 25 minutes, then 8.5 g of tetrabutyl ammonium hydrogen sulphate are charged, thereafter the reaction mixture is stirred again for 18' at 500C and 200 ml of benzene are charged and, under fast stirring, a solution of 0.3 moles of interme diate (Viii) dissolved in 250 ml of benzene, are slowly dropped in about 20'. The mixture is then refluxed for 70', cooled at room temperature, the phases are separated and the organic phase is washed with slightly acid H20, then with 1 N KOH and finally with water to neutrality. The benzenic pha se is dried on K2C03, thereafter the solvent is evaporated under reduced pressure. A crude product is obtained in a yield of 6o-8o% [intermediate ixj. The product is characterized, after crystallization from suitable solvents (for instance lower alcohols), by means of N.M.R., IR spectra and of elementary analysis. c) Prenaration of the intermediate XI In a 500 ml flask provided with stirrer, thermometer, dropping funnel and external cooling bath 100 ml of dimethylsulphoxide (anhydrous), 0.2 moles of intermediate (IX) are charged and then, un der fast stirring, a thick suspension of 21.5 g of sodium methoxide suspended in 100 ml of anhydrous dimethylsulphoxide is added in about one hour and in such a way as to not exceed 300C of internal temperature, When the addition is over, the reaction mixture is stirred again for 20' then acidified with 3 N HCl and extracted with CHCl3. After drying, the CHCl3 phase is evaporated, the residue [intermedia te (X X is dissolved in ethanol and trasformed into the hydrochloride by addition of ethanolic HCl at 000. The hydrochloride Zintermediate (XI)] is obtained in a yield of 36-67% and it often does not call for crystallizzation. It can be characterized by means of its N.M.R., I.R. spectra and of elementary analysis. d) Preparation of the intermediate (XIII) In a 500 ml flask provided with stirrer, reflux condenser, external thermostatic bath 0.15 moles of intermediate (XI), 150 ml of 1,2-dichloroethane (anhydrous) are charged, the reaction mixture is stirred for 15 at room temperature, then cooled to 2-3 C and 0.16 moles of acyl chloride R1COCl are charged in one portion. The reaction mixture is thereafter stirred for 30' at 0-5 C allowing then the temperature to raise in about 90' to 20 C, and then heated in about 60' to 60-70 C. During this heating there is development of HCl continuing again for about 3 hours. At the end the reaction mixture is allowed to cool to room temperature and the product obtained is filtered Zintermediate (XII . The intermediate (XII) is suspended in about 2QO ml of H2O and the suspension is then brought to pH = 7.3 with 10% KOH, keeping the temperature cool and under fast stirring. The suspension is stirred for about two hours and then the product obtained is filtered Zintermediate (XIII)/ which can be re-crystallized from isopropa nole and characterized by means of N.M.R., I.R. spectra and of elementary analysis. Yields are 78-92%. e) Preparation of compound (I) in a 1000 ml reactor provided with stirrer and thermometer, dropping funnel, 0.12 moles of in termediate (xiii), 400 ml of ethanol, 100 ml of water are charged. The reaction mixture is stir red for 15', then 120 ml of 1 N NaOH are added and the mixture is again stirred for 20' at room temperature; 0.38 moles of the alkyl halide RX are then charged, dropping in about 25'. The reaction is allowed to proceed for 18 hours at room temperature, the precipitate formed is filtered, wa shed with H2 0 and finally dried. Yields are 65 90%. The product is characterized by means of N.M.R., I.R. spectra and of elementary analysis. EXAMPLE 2 a) Preparation fof the intermediate (XIV) from the intermediate (X) The reaction is carried out in completely analogous conditions to those described in point e) of Example 1. Yields are 45-80%. The product obtained having formula XIV is charac terized by means of N.M.R., I.R. spectra and elementary analysis. b) Preapration of final compound I In a 1000 ml flask provided with stirrer, thermome ter, reflux condenser, dropping funnel and external thermostatic bath, 0.133 moles of the intermediate (XIV), 300 ml of anhydrous 1, 2-di- chloroethane and 6.9 g of triethylamine-are charged, the mixture is then heated to 500C and a solution of acyl halide R1COX (0.099 moles) di luted in 15 ml of dichloroethane is dropped (20'). A slight exothermia is noticed during the addition, at the end of which stirring is continued for 20' at 50 C. 6.8 g of triethylamine are then charged and stirring is continued again for 15' at 50 C, thereafter a solution of the acyl halide R1COX (0.099 moles) in 15 ml of 1,2-dich loroethane is dropped in about 20'. At the end of this second dropping, the tempera ture is still kept for 20' at 500C, the reaction mixture is then left to cool at 300C and filtered in order to remove the solid formed (triethylamine hydrochloride). The filtrate is washed with 2x200 ml of H20, then with 2 x 200 ml of 0.5 N NaOH and finally with H20 to neutrality. The solution in 1,2-dichlcroethane is dried on Na2SO4, the solvent is then evaporated under vacuum till the obtaining of an oil which immediately solidifies and which is well plS ped in ethyl ether. The suspension is filtered, washed with ethyl ether and the solid obtained, which does not require re-crystallization, is dried. Yields are 75-90g0. The products are cha racterized by means of N.M.R., I.R. spectra and of elementary analysis. With the above described methods, the following products are obtained: EMI16.1 4-Pivaloyloxy-2-methyl-2H-1,2-benzothiazine-3-b-(2- pyridyl)-carboxamide]-1,1-dioxide. White crystalline powder melting at 152-154 C. ÚH-NMR SPECTRUM at 60MHz (CDCl3) (ppm, #) ) = 9.0 (s, broad, mobile -NH-); 8.35-8.15 (m, 2H = H-5 and H-6 of the pyridine ring); 8.0-7.4 [m, 5H (4 aromatics + H-3 of the pyridine ring)7; 7.3-6.9 (m, 1H = H-4 of the pyridine ring); 3.05 (s, 3H = -N-CH3); 1.4 [s, 9H = -CH3)3g. -1 I.R. SPECTRUM (KBr) 3700-3150 cm (broad); 2980 cm (weak); 1760 cm-1; 1680 cm 1530 cm-1; 1435 cm-1; 1350 cm-1; 1300 cm-1; 1090 cm-1; 765 cm-1. ELEMENTARY ANALYSIS (C, H, N) for C20H21N3O5S calcd, % C = 57.82; H = 5.095; N = 10.11 found % C = 57.69; H = 5,087; N = 10.28. EMI17.1 4-Pivaloyloxy-2-methyl-2H-1,2-benzothiazine-3-N (2-thiazolyl)carboxamide]-1,1-dioxide. White cream powder melting at 175-177 C. H-wER SPECTRUM at 60 MHz (CDCl ) 3 (ppm, d) = 11.1-9.9 (s, broad 1H mobile -NH-); 8.0-7.55 (m, 4H, aromatics); 7.5 and 7.0 (2 doublets of 1H each, J # 4Hz = 2H thiazolics); 3.0 (s, 3H = N-CH3); 1.4 (s, 9H = -C(CH3)3). I.R. SPECTRUM (KBr) 3680-3220 cm (broad); 2980 cm (weak) -1 -1 -1 -1 1769 cm; 1675 cm; 1560 cm; 1530 cm; 1350 cm-1; 1180 cm-1; 760 cm-1; 720 cm-1. ELEMENTARY ANALYSIS (C, H, N) for C18H19N3 055 calcd. % C = 51.29; H = 4.54; N = 9.97 found % C = 51.20;.H = 4.46; N = 10.01. The compounds object of the present invention have been characterized from the toxico-pharmacological point of view. We report the results obtained with the compound 4-pivaloyloxy-3-methyl-2H-1,2-benzothiazine-3-AN-(2- pyridyl)-carboxamide]-1,1-dioxide (CHF 1021) and 4-pivaloyloxy-2-methyl-2H-1,2-benzothiazine-3-[N (2-thiazolyl)-carboxmide]-1,1-dioxide (CHF 1047). In these studies the activity of compounds CHF 1021 and CHF 1047 has been compared with the one of piroxicam, one of the most active oxicam previously described, by now entered into the therapeutic practice, and with the one of two other esters: valerate and n-butyrrate of piroxicam (respectively CHF 1109 and C1 1115). Acute toxicity The toxicity by single administration has been determined by oral route in male mice IVA:N (SPF), fasting, with water ad libitum 18 hours before the experiment. The substances under exam were suspended in 1% carboxymethylcellulose. The results relative to the approximate LD50 values, determined by interpolation on Probitpaper, have been reported in Table I. TABLE I EMI18.1 <tb> Compound <SEP> Approx. <SEP> LD50 <tb> <SEP> mg/kg <tb> CHF <SEP> 1021 <SEP> 1800 <tb> CHF <SEP> 1047 <SEP> > 3000 <SEP> <tb> CHF <SEP> 1109 <SEP> 1100 <tb> CHF <SEP> 1115 <SEP> 880 <tb> <SEP> Piroxicam <SEP> 345 <tb> Antiinflammatory activity in the test of plantar edema by carrageenin Crl: CD(SD) male rats, weighing 170-205 g, previously subjected to an acclimation period of at least one week through housing in environment with costant thermohygrometric conditions and fa sting with water ad libitum 18 hours before the start of the test, have been distributed "at ran dom" in groups of 5-6 animals each (4 groups cor responding to 4 different dose levels for each compound). A group of control animals has been treated only with the vehicle. The test has been performed in 2 subsequent expe rimental sessions: 1: piroxicam versus CHF 1021 2: piroxicam versus CHF 1047, CHF 1109 and CHF 1115. The activity of the examined compounds, administered at different doses, by the oral route, has been valued by measuring the protection offered against the development of the oedema induced in the rat's paw by injecting (at a distance of one hour from the administration of the active princi ple) 0.1 ml of 1% carrageenin in physiologic solution in the subplantar aponeurosis of the rear right paw, according to the method of Winter (Win ter C.A. et al., Proc. Soc. Exp. Biol. Med. 111, 544, 1962). The volume of the treated paw has been measured by means of a water-mercury pletismometer according to Leuce P., Arch. Int. Pharmacodyn. 136, 237, 1962) immediately before and at different ti mes adter injection of the phlogogenic agent0 The results have been expressed as ED30 values calculated on the logarithmic regression straight lines of the percent dose/inhibition of the oedema development, in turn determined from the ratio between the mean AUG value (area under the curve representing the development of the paw volume in the time) in the different treated animals groups and the respective control groups. Such results are shown in the Table II. Gastrolesive activity On the same animals on which the antiinflammatory activity has been determined, the gastrolesivity has been contemporaneously checked through macroscopic control of the gastric mucosa at a di stance of 7 hours from the administration of the substance under examination. For each treatment, the logarithmic regression straight lines of the dose - mm of ulceration (single values of each animal) have been determi ned. On the ground of such lines the calculation of U33 values, that is a dose whereby a gastric lesion of the total extension of 3 mm is expected, has been performed. The results obtained are shown in Figure II. From the examination of the results, altogether represented in the table I and II the following considerations can be found. The compound CHF 1021 endowed with remarkable antiinflammatory activity, comparable to the one of the reference compound (piroxicam)surprisingly exhibits an ulcerogenic activity at least 10 times lower and an acute toxi city about 35% lower in comparison to the reference compound. These properties of important antiinflammatory ac tivity with considerable decrease of the ulceroge nic effect, constituting the most serious side-ef fect of non-steroidal antiinflammatory drugs, con fer to the product in question a very remarkable therapeutic interest and they turn out so much un expected if compared with the results obtained with the other analogous derivatives contemporaneously tested. In fact: - the compound CHF 1047 or pivalic ester of 4-hy droxy-2-methyl-2H-1,2-benzothiazine-3-[N-(2-thia zolyl)-carboxamid2/-1,1-dioxide (sudoxicam) presented a very low antiinflammatory activity. His direct parent compound, sudoxicam, on the con trary, had explicated in analogous tests an antiin flammatory activity comparable to the one of piroxicam, our reference drug (Wiseman E.H., Lombardi no J.G.: Oxicams - A novel family of Non-Stercidal Anti-inflammatory Drugs - Eur. J. Rheumatol. In- flamm. 4(3), 280, 1981). In this case, therefore, the esterification, at least with this kind of substituent, determined a very high loss of activity. TABLE II: Data of the comparasion tests between compound CHF 1021, CHF 1047, CHF 1109, CHF 115 and piroxicam. Values of ED30 (antiinflammatory activity) and of UD3 (gasrolesive activi ty) are relative to the oral route and are expressed in mol/kg EMI23.1 Exp. <SEP> Compounds <SEP> Antiinflammatory <SEP> Gastrolesive <SEP> Therapeutic <SEP> Relative <tb> session <SEP> activity <SEP> activity <SEP> index <SEP> therapeu <tb> <SEP> ED30 <SEP> ( mol/kg) <SEP> UD3 <SEP> ( mol/kg) <SEP> UD3/ED30 <SEP> tic <SEP> in <SEP> dex* <tb> <SEP> piroxicam <SEP> 7.8 <SEP> 9.3 <SEP> 1.2 <SEP> 1 <tb> <SEP> I <SEP> CHF <SEP> 1021 <SEP> 7.9 <SEP> 97.2 <SEP> 12.3 <SEP> 10.25 <tb> <SEP> piroxicam <SEP> 9.7 <SEP> 27.2 <SEP> 2.8 <SEP> 1 <tb> <SEP> II <SEP> CHF <SEP> 1047 <SEP> #762 <SEP> 121.2 <SEP> 0.2 <SEP> 0.07 <tb> <SEP> CHF <SEP> 1109 <SEP> 7.0 <SEP> 28.2 <SEP> 4.0 <SEP> 1.43 <tb> <SEP> CHF <SEP> 1115 <SEP> 5.7 <SEP> 23.9 <SEP> 4.2 <SEP> 1.50 <tb> * Therapeutic index relative to piroxicam considered as 1. - Compounds CHF 1109 and 1115 although having a good antiinflammatory activity, analogous or also slightly higher than the one of the parent compound, do not show an improvement of tolerabi lity (on the contrary CHF 1115, n-butirryl ester of piroxicam, is slightly more ulcerogenic with a potency ratio of 0.88 to 1), whereby their relative therapeutic index is a little higher than the one of the reference compound: respectively 1.43 and 1.50. Other oharmacological characteristics of CHF 1021 In other tests of direct comparison between piro xicam and CHF 1021, the latter confirmed its anti inflammatory activity, along with a good analgesic and antipiretic activity. The potency ratios (ratios between ED50 values) calculated on molar basis point out that CHF 1021 is 1.52-0.49-0.72- 0.71 times as active as the reference compound on the plantar oedema by nystatin in the rat, on the erythema by U.V. in the guinea pig, on the writhing test by phenylquinone in the mouse and on the fever by beer's yeast in the reat. The two compounds are almost equally active on the arthri tis by adjuvant in the rat. Preliminar clinical data allowed to point out that CHE 1021 confirms to be a valid antiinflammatory drug practically equally active in comparison with piroxicam but with a clearly lower incidence of side effects (about 1/3 than that of the reference drug). The present mvention refers moreover to pharmaceutical compositions containing as the active princi ple a compound of formula (I), as defined above, as such or as a pharmaceutically acceptable salt, in association with at least one pharmaceutically acceptable excipient. The compositions can be administered orally, paren terally or topically, in the form respectively of capsules, tablets or similar compositions, supposi tories, vials, cream or gel. For the preparation of the pharmaceutical formula tion for the oral administration in unitary dose, the active principle can be mixed with a solid pow dered, excipient, such as for instance lactose, saccharose, sorbitol, mannitol, potato or cereal or maize starch, or amylopectin, a derivative of cellulose or gelatin, and it can moreover contain lu bricant such as talcum, polyethylenglyccle or silica, magnesium or calcium stearate, The tablets can be variously coated according to well-known methods in the pharmaceutical art. Capsules of hard gelatin can contain granulates of the active principle together with solid powdered excipients, such as lactose, saccharose, sorbi tol, mannitol, starches (of the kind indicated abo ve), cellulose or gelatin derivatives, and they may also contain stearic acid or magnesium stearate or talcum. Unitary doses for rectal administration may be in the form of suppositories containing the active principle in association with a neutral fat base (example glycerides of fat acids) or with water-soluble or autoemulsifiable eipients (example polyethylenglycole mixtures). For injectable compositions for parenteral admi nistration, the excipients can be a pharmaceuti cally acceptable sterile liquid such as water or an aqueous solution of polyvinylpyrrolydone or, again, an oil such as, for instance, peanutoil and, if necessary a stabilizing agent and/or a buffer. The active principle can be dissolved in the li quid and sterilized on filter before being put in a vial or it can be suitably lyophilized; in this case vials of liquid for injections will be added in the packagings in order to reconsti tute the solution before use. In the case both of the composition in suppositories and in vials a local anaesthetic, if necessary, can be added to the excipients, The unitary dose for the formiations described above can vary from 10 to 200 mg of active principle and the daily administration will be preferably single. For the preparation of formulations for topic use, fat-base excipients, such as vaseline, pa raffin oil, lanoline etc. can be used, as well as autoermilsifiable excipients such as alcohols, fats, polyethylenglycoles, ethers or esters of fat acids or other tensides emulsified in water in the case of unguents, ointments and creams. On the contrary, in the case of preparations of gel of hydrophylic colloids, polymers of different kinds will be used, such as carboxyvynylpolymers, sodium carboxymethyl cellulose, methylcellulose, Methocel gelatinized in water, ethanol, propylenglycol, glycerole, polyethylenglycols, etc. The topic preparations indicated above can be advantageously added to suitable antibacterial agents, such as parabens, phenol derivatives quaternary ammonium salts, etc. The concentration of the active principle can vary in these compositions from 1 to 10%. We report some formulations as exemplification. Formulation in hard gelatin capsules for oral administraions Composition at three different dosages: CHF 1021 mg 30 40 60 Microcrystalline cellulose (Avicel ) II 37.5 35 30 Dihydrated dibasic calcium phosphate (Encompress) " 105 98 84 Talcum " 6.54 6.1 5.23 Magnesium stearate tt 0.96 0.9 0.77 For the preparation of N. 5000 capsules, with the components that are proportionally present in the above-defined quantities in relation to the dosage of the active principle, the following operations are carried out. The raw materials are sieved, they are loaded in a powder mixer, the mixture is homogenized. The homogeneous mixture thus obtained is divided into capsules or opercula of hard gelatin by means of operculum-machine. The weight of unitary mixture for capsule is of 180 mg. Formulations in suppositories for rectal administriation Composition at three different dosages: ONE 1021 mg 30 60 100 Semi-synthetic glycerides " 1570 1540 1500 (Witepol For the preparation of N. 5000 suppositories, with the components that are proportionally present in the above-defined quantities in relation to the do sage of the active principle, the following operations are carried out. The mass of excipient is melted at 400C, The active principle is incorporated in the melted mass operating with a suitable mechanic dispersant. The mass is cooled at 360C and it is poured, keeping the suppository mass under stirring, in PVC or alu minium valves having the unitary volume of 1.8 ml. The weight of the suppository mass distributed for each valve is of 1.6 g. It is let solidify and the containers are suitably sealed. Formulations in cream for topic administration Composition at two different dosages of a cream of oil-water etmilsion kind: CHF 1021 g 2 5 Octyldodecanole (Eutanol G # ) " 7 7 Liquid triglyceride C8 N 3 3 (iritol 218 #) Polioxyethylene cetostearyl n 2 2 alcohol (Emulgin B1/B2(2) Propylenic glycole " 5 5 Carboxyvinylpolymer 1 1 (Carbopol 940 #) Fenocombin # " 1 1 Sodium hydroxide Q.S.at pH 5.5 Q.S.at pH 5.5 Purified water " " g 100 " " g 100 For the preparation of kg 5 of cream, with the components that are proportionally present in the above-defined quantities in relation to the concentration of the active principle, the following operations are carried out. The carboxyvinylpolymer is dispersed in water (20% of the quantity necessary to the prepara tion of the lot) and it is neutralized with so da in the quantity required to obtain a pH 5.5. The components and the fat phase are united in a suitable foundry and they are melted at the tem perature of 700C. The active principle CHF 1021 is dispersed in glycol and water (1051o of the quantity necessary to the preparation of the lot), the preservative is dissolved in the residual quantity of water and the solution is taken to 800C. The aqueous phase is poured in the fat phase carrying out the homogenization with suitable emul sifter It is cooled to 400C and the emulsion is added with the hydroglycolic suspension of the ac tive principle. The emulsion is finally stabilized with the gel of CV Polymer added and dispersed by means of suitable mechanic stirrer. pH Is checked and adjusted at 5.5. Cream is distributed in flexible aluminium tubes or in other suitable packaging material for prepa rations for topic use.

Claims: Claims: 1. Compounds of general formula (I) EMI31.1 where R stands for a lower alkyl C C1-C4; R1 stands for a linear or a branched alkyl bearing from 1 to 5 atoms of carbon atoms; Ar stands for an aromatic or heteroaromatic mono or bicyclic residue bearing from 1 to 3 heteroatoms such as 0, S, N and preferably the residues 2-pyridyl, 2-thiazolyl. 2. 4-Pivaloyloxy-2-methyl-2H-1,2,-benzothiazine-3 [N-(2-pyridyl)-carboxamide[-1,1-dioxide. 3. 4-Pivaloyloxy-2-methyl-2H-1,2-benzothiazine-3 [N-(2-thiazolyl)-carboxamide]-1,1-dioxide. 4. Process for the preparation of the compounds of claim 1, characterized in that: a N-arylchloroacetamide (VIII) X-CH2-CONH-Ar (VIII) where X meas a halogen atom and Ar has the meaning indicated in claim 1 is reacted with the intermediate (VII) of formula EMI32.1 to obtain a compound of the general formula (tK) EMI32.2 where Ar has the above indicated meaning and in a single step compound (TX) turns into the benzothia zinic derivative (X) of formula: EMI32.3 where Ar has the above indicated meaning and compound (X), as such or in the form of one of its addition salts, is esterified at the hydroxyl group by reaction with an acylating agent and it is finally alkylated at the nitrogen atom in 2. 5. Process according to claim 4, characterized in that the transformation of IX in X takes place in the presence of sodium methoxide and dime thylsulfoxide at temperature no higher than 30 35owe 6. Process according to claim 4, characteri zed in that the esterifiation reaction can take place in the absence or in the presence of solvents, bases and catalysts and at temperatures ranging from 0 to 1000C, preferably at room tem perature. 7. Pharmaceutical formulation at analgesic and antirheumatic activity, containing as active principle a compound according to claim 1, or one of one of its pharmaceutically acceptable salts. 8. Pharmaceutical formulation according to claim 7 for oral, rectal or parenteral administration in the form of capsules, tablets coated if necessary, suppositories or vials, containing from 10 to 200 mg of active principle per unit dose. 9. Pharmaceutical composition according to claim 7, for topic administration, in the form of cream or gel, containing the active principle in concentration from 1 to 10%. Claim: 1. Process for the preparation of compounds of general formula (I) EMI34.1 where R stands for a lower alkyl C1-C4; R1 stands for a linear or a branched alkyl bearing from 1 to 5 atoms of carbon atoms; Ar stands for an aromatic or heteroaromatic mono or bicyclic residue bearing from 1 to 3 heteroatoms such as 0, S, N and preferably the residues 2-pyridyl, 2-thiazolyl, characterized in that: a N-arylchloroacetamide (VIII) X-CH2-CONH-Ar (VIII) where X means a halogen atom and Ar has the above indicated meaning, is reacted with the intermedia te (VII) of formula EMI34.2 to obtain a compound of the general formula (IX) EMI35.1 where Ar has the above indicated meaning and in a single step compound (IX) turns into the benzothia zinic derivative (X) of formula: EMI35.2 where Ar has the above indicated meaning, and compound (X), as such or in the form of one of its addition salts, is esterified at the hydroxyl group by reaction with an acylating agent and it is finally alkylated at the nitrogen atom in 2. 2. Process according to claim 1, characterized in that the transformation of IX in X takes place in the presence of sodium methoxide and dime thylsulfoxide at temperature no higher than 30350C. 3. Process according to claim 1, characteri zed in that the esterifiation reaction can take place in the absence or in the presence of solvents, bathes and catalysts and at temperatures ranging from 0 to 1000C, preferably at room tern perature. 4. Process according to claims 1-3, characte rized in that R is methyl, R1 is t.butyl and Ar is 2-pyridyl. 5. Process according to claims 1-3, characterized in that R is methyl, R1 is t.butyl and Ar is 2-thiazolyl.

Inventors: CHIESI, PAOLO, VILLANI, FLAVIO
Applicants: CHIESI FARMACEUTICI S.P.A.
Application year: 1983
Main classification: C07D417
IPC codes: C07D275, C07D417